Imatinib mesilate: new perspectives in the treatment of solid tumours

Bibliography

• SAVAGE DG, ANTMAN KH: Imatinib mesylate–a new oral targeted therapy. N. Engl. J. Med. (2002) 346(9):683-693.
   PubMed Web of Science ®Google Scholar
• COHEN MH, WILLIAMS G, JOHNSON JR et al.: Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin. Cancer Res. (2002) 8(5):935-942.
   PubMed Web of Science ®Google Scholar
• RADFORD IR: Imatinib. Novartis. Curr. Opin. Investig. Drugs (2002) 3(3):492-499.
   PubMedGoogle Scholar
• SCHLESSINGER J: Cell signaling by receptor tyrosine kinases. Cell (2000) 103(2):211-225.
   PubMed Web of Science ®Google Scholar
• VAN ETTEN RA: c-Abl regulation: a tail of two lipids. Curr. Biol. (2003) 13(15):R608-R610.
   Google Scholar
• BLUME-JENSEN P, HUNTER T: Oncogenic kinase signalling. Nature (2001) 411(6835):355-365.
   PubMed Web of Science ®Google Scholar
• KOLIBABA KS, DRUKER BJ: Protein tyrosine kinases and cancer. Biochim. Biophys. Acta (1997) 1333(3):F217-F248.
   PubMed Web of Science ®Google Scholar
• BARTRAM CR, DE KLEIN A, HAGEMEIJER A et al.: Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature (1983) 306(5940):277-280.
   PubMed Web of Science ®Google Scholar
• GROFFEN J, STEPHENSON JR, HEISTERKAMP N et al.: Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell (1984) 36(1):93-99.
   PubMed Web of Science ®Google Scholar
• GRIFFIN JD: Phosphatidyl inositol signaling by BCR/ABL: opportunities for drug development. Cancer Chemother. Pharmacol. (2001) 48(Suppl. 1):S11-S16.
   PubMed Web of Science ®Google Scholar
• NAKAO M, YOKOTA S, IWAI T et al.: Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia (1996) 10(12):1911-1918.
   PubMed Web of Science ®Google Scholar
• SHIMIZU A, O'BRIEN KP, SJOBLOM T et al.: The dermatofibrosarcoma protuberans-associated collagen type Iα1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Res. (1999) 59(15):3719-3723.
   PubMed Web of Science ®Google Scholar
• GOLUB TR, BARKER GF, LOVETT M, GILLILAND DG: Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell (1994) 77(2):307-316.
   PubMed Web of Science ®Google Scholar
• GILLILAND G, COOLS J, STOVER EH, WLODARSKA I, MARYNEN P: FIP1L1-PDGFRα in hypereosinophilic syndrome and mastocytosis. Hematol. J. (2004) 5(Suppl. 3):S133-S137.
   Google Scholar
• PIETRAS K, SJOBLOM T, RUBIN K, HELDIN CH, OSTMAN A: PDGF receptors as cancer drug targets. Cancer Cell (2003) 3(5):439-443.
   PubMed Web of Science ®Google Scholar
• HIROTA S, ISOZAKI K, MORIYAMA Y et al.: Gain-of-function mutations of c-KIT in human gastrointestinal stromal tumors. Science (1998) 279(5350):577-580.
   PubMed Web of Science ®Google Scholar
• NISHIDA T, HIROTA S, TANIGUCHI M et al.: Familial gastrointestinal stromal tumours with germline mutation of the KIT gene. Nat. Genet. (1998) 19(4):323-324.
   PubMed Web of Science ®Google Scholar
• TIAN Q, FRIERSON HF Jr, KRYSTAL GW, MOSKALUK CA: Activating c-KIT gene mutations in human germ cell tumors. Am. J. Pathol. (1999) 154(6):1643-1647.
   PubMed Web of Science ®Google Scholar
• KITAMURA Y, HIROTA S, NISHIDA T: A loss-of-function mutation of c-KIT results in depletion of mast cells and interstitial cells of Cajal, while its gain-of-function mutation results in their oncogenesis. Mutat. Res. (2001) 477(1-2):165-171.
   PubMed Web of Science ®Google Scholar
• LONGLEY BJ Jr, METCALFE DD, THARP M et al.: Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc. Natl. Acad. Sci. USA (1999) 96(4):1609-1614.
   PubMed Web of Science ®Google Scholar
• PIETSCH T, NICOTRA MR, FRAIOLI R et al.: Expression of the c-KIT receptor and its ligand SCF in non-small-cell lung carcinomas. Int. J. Cancer (1998) 75(2):171-175.
   PubMed Web of Science ®Google Scholar
• KITAMURA Y, HIROTAB S: KIT as a human oncogenic tyrosine kinase. Cell. Mol. Life Sci. (2004) 61(23):2924-2931.
   PubMed Web of Science ®Google Scholar
• BORDEN EC, BAKER LH, BELL RS et al.: Soft tissue sarcomas of adults: state of the translational science. Clin. Cancer Res. (2003) 9(6):1941-1956.
   PubMed Web of Science ®Google Scholar
• SUN L, HUI AM, SU Q et al.: Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell (2006) 9(4):287-300.
   PubMed Web of Science ®Google Scholar
• HOU YY, TAN YS, XU JF et al.: Schwannoma of the gastrointestinal tract: a clinicopathological, immunohistochemical and ultrastructural study of 33 cases. Histopathology (2006) 48(5):536-545.
   PubMed Web of Science ®Google Scholar
• UCCINI S, MANNARINO O, MCDOWELL HP et al.: Clinical and molecular evidence for c-KIT receptor as a therapeutic target in neuroblastic tumors. Clin. Cancer Res. (2005) 11(1):380-389.
   PubMed Web of Science ®Google Scholar
• MOJICA WD, SAXENA R, STAROSTIK P, CHENEY RT: CD117+ small cell lung cancer lacks the asp 816–val point mutation in exon 17. Histopathology (2005) 47(5):517-522.
   PubMed Web of Science ®Google Scholar
• KIM DJ, LEE MH, PARK TI, BAE HI: Expression and mutational analysis of c-KIT in ovarian surface epithelial tumors. J. Korean Med. Sci. (2006) 21(1):81-85.
   PubMed Web of Science ®Google Scholar
• BELLONE G, SMIRNE C, CARBONE A et al.: KIT/Stem cell factor expression in premalignant and malignant lesions of the colon mucosa in relationship to disease progression and outcomes. Int. J. Cancer (2006) (in Press)
   Google Scholar
• WATANABE D, EZOE S, FUJIMOTO M et al.: Suppressor of cytokine signalling-1 gene silencing in acute myeloid leukaemia and human haematopoietic cell lines. Br. J. Haematol. (2004) 126(5):726-735.
   PubMed Web of Science ®Google Scholar
• KAO KR, BERNSTEIN A: Expression of Xkl-1, a Xenopus gene related to mammalian c-KIT, in dorsal embryonic tissue. Mech. Dev. (1995) 50(1):57-69.
   PubMed Web of Science ®Google Scholar
• CHOUDHURY HR, SHEIKH NA, BANCROFT GJ, KATZ DR, DE SOUZA JB: Early nonspecific immune responses and immunity to blood-stage nonlethal Plasmodium yoelii malaria. Infect. Immun. (2000) 68(11):6127-6132.
   PubMed Web of Science ®Google Scholar
• MANOVA K, HUANG EJ, ANGELES M et al.: The expression pattern of the c-KIT ligand in gonads of mice supports a role for the c-KIT receptor in oocyte growth and in proliferation of spermatogonia. Dev. Biol. (1993) 157(1):85-99.
   PubMed Web of Science ®Google Scholar
• BUCHDUNGER E, ZIMMERMANN J, METT H et al.: Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc. Natl. Acad. Sci. USA (1995) 92(7):2558-2562.
   PubMed Web of Science ®Google Scholar
• ZIMMERMANN J, CARAVATTI G, METT H et al.: Phenylamino-pyrimidine (PAP) derivatives: a new class of potent and selective inhibitors of protein kinase C (PKC). Arch. Pharm. (Weinheim) (1996) 329(7):371-376.
   PubMed Web of Science ®Google Scholar
• DRUKER BJ, TAMURA S, BUCHDUNGER E et al.: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. platelet-derived growth factor receptorNat. Med. (1996) 2(5):561-566.
   PubMed Web of Science ®Google Scholar
• BUCHDUNGER E, ZIMMERMANN J, METT H et al.: Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. (1996) 56(1):100-104.
   PubMed Web of Science ®Google Scholar
• CARROLL M, OHNO-JONES S, TAMURA S et al.: CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood (1997) 90(12):4947-4952.
   PubMed Web of Science ®Google Scholar
• BERAN M, CAO X, ESTROV Z et al.: Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148). Clin. Cancer Res. (1998) 4(7):1661-1672.
   PubMed Web of Science ®Google Scholar
• GAMBACORTI-PASSERINI C, LE COUTRE P, MOLOGNI L et al.: Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol. Dis. (1997) 23(3):380-394.
   PubMed Web of Science ®Google Scholar
• DEININGER MW, VIEIRA S, MENDIOLA R et al.: BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia. Cancer Res. (2000) 60(7):2049-2055.
   PubMed Web of Science ®Google Scholar
• HEINRICH MC, GRIFFITH DJ, DRUKER BJ et al.: Inhibition of c-KIT receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood (2000) 96(3):925-932.
   PubMed Web of Science ®Google Scholar
• CARROLL M, TOMASSON MH, BARKER GF, GOLUB TR, GILLILAND DG: The TEL/platelet-derived growth factor-β receptor (PDGF β R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF-β R kinase-dependent signaling pathways. Proc. Natl Acad. Sci. USA (1996) 93(25):14845-14850.
   PubMed Web of Science ®Google Scholar
• NAGAR B, BORNMANN WG, PELLICENA P et al.: Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. (2002) 62(15):4236-4243.
   PubMed Web of Science ®Google Scholar
• DRUKER BJ: Imatinib alone and in combination for chronic myeloid leukemia. Semin. Hematol. (2003) 40(1):50-58.
   PubMed Web of Science ®Google Scholar
• O'BRIEN SG, GUILHOT F, LARSON RA et al.: Imatinib compared with IFN and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. (2003) 348(11):994-1004.
   PubMed Web of Science ®Google Scholar
• GOLDMAN JM, MELO JV: Chronic myeloid leukaemia–advances in biology and new approaches to treatment. N. Engl. J. Med. (2003) 349(15):1451-1464.
   PubMed Web of Science ®Google Scholar
• DE MESTIER P, DES GUETZ G: Treatment of gastrointestinal stromal tumors with imatinib mesylate: a major breakthrough in the understanding of tumor-specific molecular characteristics. World J. Surg. (2005) 29(3):357-361; discussion 362.
   PubMed Web of Science ®Google Scholar
• DE SILVA CM, REID R: Gastrointestinal stromal tumors (GIST): C-KIT mutations, CD117 expression, differential diagnosis and targeted cancer therapy with Imatinib. Pathol. Oncol. Res. (2003) 9(1):13-19.
   PubMed Web of Science ®Google Scholar
• MOSKALUK CA, TIAN Q, MARSHALL CR et al.: Mutations of c-KIT JM domain are found in a minority of human gastrointestinal stromal tumors. Oncogene (1999) 18(10):1897-1902.
   PubMed Web of Science ®Google Scholar
• LUX ML, RUBIN BP, BIASE TL et al.: KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am. J. Pathol. (2000) 156(3):791-795.
   PubMed Web of Science ®Google Scholar
• HEINRICH MC, RUBIN BP, LONGLEY BJ, FLETCHER JA: Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum. Pathol. (2002) 33(5):484-495.
   PubMed Web of Science ®Google Scholar
• JOENSUU H, ROBERTS PJ, SARLOMO-RIKALA M et al.: Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med. (2001) 344(14):1052-1056.
   PubMed Web of Science ®Google Scholar
• VAN OOSTEROM AT, JUDSON I, VERWEIJ J et al.: Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a Phase I study. Lancet (2001) 358(9291):1421-1423.
   PubMed Web of Science ®Google Scholar
• HEINRICH MC, CORLESS CL, DEMETRI GD et al.: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. (2003) 21(23):4342-4349.
   PubMed Web of Science ®Google Scholar
• DES GUETZ G, DE MESTIER P, PIERGA JY: At last, an effective therapy for non-differentiated GI sarcomas (gastrointestinal stromal tumor). J. Chir. (Paris) (2002) 139(5):268-273.
   PubMedGoogle Scholar
• DEMETRI GD, VON MEHREN M, BLANKE CD et al.: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. (2002) 347(7):472-480.
   PubMed Web of Science ®Google Scholar
• FLETCHER CD, BERMAN JJ, CORLESS C et al.: Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum. Pathol. (2002) 33(5):459-465.
   PubMed Web of Science ®Google Scholar
• VAN DER ZWAN SM, DEMATTEO RP: Gastrointestinal stromal tumor: 5 years later. Cancer (2005) 104(9):1781-1788.
   PubMed Web of Science ®Google Scholar
• PANTALEO MA, PALASSINI E, LABIANCA R, BIASCO G: Targeted therapy in colorectal cancer: do we know enough? Dig. Liver Dis. (2006) 38(2):71-77.
   Google Scholar
• BELLONE G, CARBONE A, SIBONA N et al.: Aberrant activation of c-KIT protects colon carcinoma cells against apoptosis and enhances their invasive potential. Cancer Res. (2001) 61(5):2200-2206.
   PubMed Web of Science ®Google Scholar
• BELLONE G, FERRERO D, CARBONE A et al.: Inhibition of cell survival and invasive potential of colorectal carcinoma cells by the tyrosine kinase inhibitor STI571. Cancer Biol. Ther. (2004) 3(4):385-392.
   PubMed Web of Science ®Google Scholar
• CAO D, ANTONESCU C, WONG G et al.: Positive immunohistochemical staining of KIT in solid-pseudopapillary neoplasms of the pancreas is not associated with KIT/PDGFRA mutations. Mod. Pathol. (2006).
   PubMed Web of Science ®Google Scholar
• KIM R, EMI M, ARIHIRO K et al.: Chemosensitization by STI571 targeting the platelet-derived growth factor/platelet-derived growth factor receptor-signaling pathway in the tumor progression and angiogenesis of gastric carcinoma. Cancer (2005) 103(9):1800-1809.
   PubMed Web of Science ®Google Scholar
• MILIARAS D, KARASAVVIDOU F, PAPANIKOLAOU A, SIOUTOPOULOU D: KIT expression in fetal, normal adult, and neoplastic renal tissues. J. Clin. Pathol. (2004) 57(5):463-466.
   PubMed Web of Science ®Google Scholar
• SULZBACHER I, BIRNER P, TRAXLER M, MARBERGER M, HAITEL A: Expression of platelet-derived growth factor-α receptor is associated with tumor progression in clear cell renal cell carcinoma. Am. J. Clin. Pathol. (2003) 120(1):107-112.
   PubMed Web of Science ®Google Scholar
• AMATO RJ: Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens. Ann. Oncol. (2005) 16(1):7-15.
   PubMed Web of Science ®Google Scholar
• VUKY J, ISACSON C, FOTOOHI M et al.: Phase II trial of imatinib (Gleevec) in patients with metastatic renal cell carcinoma. Invest. New Drugs (2006) 24(1):85-88.
   PubMed Web of Science ®Google Scholar
• HAITEL A, SUSANI M, WICK N, MAZAL PR, WRBA F: c-KIT overexpression in chromophobe renal cell carcinoma is not associated with c-KIT mutation of exons 9 and 11. Am. J. Surg. Pathol. (2005) 29(6):842.
   PubMed Web of Science ®Google Scholar
• SENGUPTA S, CHEVILLE JC, CORLESS CL et al.: Rare expression of KIT and absence of KIT mutations in high grade renal cell carcinoma. J. Urol. (2006) 175(1):53-56.
   PubMed Web of Science ®Google Scholar
• LOKKER NA, SULLIVAN CM, HOLLENBACH SJ, ISRAEL MA, GIESE NA: Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res. (2002) 62(13):3729-3735.
   PubMed Web of Science ®Google Scholar
• RAYMOND E, BRANDES A, VAN OOSTEROM A et al.: Multicentre Phase II study of imatinib mesylate in patients with recurrent glioblastoma: an EORTC: NDDG/BTG intergroup study (Abstract). J. Clin. Oncol. (2004) 22:S107.
   Web of Science ®Google Scholar
• REARDON DA, EGORIN MJ, QUINN JA et al.: Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J. Clin. Oncol. (2005) 23(36):9359-9368.
   PubMed Web of Science ®Google Scholar
• DRESEMANN G: Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series. Ann. Oncol. (2005) 16(10):1702-1708.
   PubMed Web of Science ®Google Scholar
• STUPP R, HEGI ME, VAN DEN BENT MJ et al.: Changing paradigms – an update on the multidisciplinary management of malignant glioma. Oncologist (2006) 11(2):165-180.
   PubMed Web of Science ®Google Scholar
• MICKE P, BASRAI M, FALDUM A et al.: Characterization of c-KIT expression in small cell lung cancer: prognostic and therapeutic implications. Clin. Cancer Res. (2003) 9(1):188-194.
   PubMed Web of Science ®Google Scholar
• WOLFF NC, RANDLE DE, EGORIN MJ, MINNA JD, ILARIA RL Jr: Imatinib mesylate efficiently achieves therapeutic intratumor concentrations in vivo but has limited activity in a xenograft model of small cell lung cancer. Clin. Cancer Res. (2004) 10(10):3528-3534.
   PubMed Web of Science ®Google Scholar
• JOHNSON BE, FISCHER T, FISCHER B et al.: Phase II study of imatinib in patients with small cell lung cancer. Clin. Cancer Res. (2003) 9(16 Pt 1):5880-5887.
   PubMed Web of Science ®Google Scholar
• KRUG LM, CRAPANZANO JP, AZZOLI CG et al.: Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-KIT protein: a Phase II clinical trial. Cancer (2005) 103(10):2128-2131.
   PubMed Web of Science ®Google Scholar
• DY GK, MILLER AA, MANDREKAR SJ et al.: A Phase II trial of imatinib (ST1571) in patients with c-KIT expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. Ann. Oncol. (2005) 16(11):1811-1816.
   PubMed Web of Science ®Google Scholar
• JOHNSON FM, KRUG LM, TRAN HT et al.: Phase I studies of imatinib mesylate combined with cisplatin and irinotecan in patients with small cell lung carcinoma. Cancer (2006) 106(2):366-374.
   PubMed Web of Science ®Google Scholar
• OUDARD S, MEDIONI J, SCOTTE F, BANU E: Prostate cancer: update. Bull. Cancer (2005) 92(10):865-873.
   PubMed Web of Science ®Google Scholar
• MATHEW P, FIDLER IJ, LOGOTHETIS CJ: Combination docetaxel and platelet-derived growth factor receptor inhibition with imatinib mesylate in prostate cancer. Semin. Oncol. (2004) 31(2 Suppl. 6):24-29.
   PubMed Web of Science ®Google Scholar
• KANTOFF P: Recent progress in management of advanced prostate cancer. Oncology (Williston Park) (2005) 19(5):631-636.
   PubMed Web of Science ®Google Scholar
• MCARTHUR GA: Dermatofibrosarcoma protuberans: a surgical disease with a molecular savior. Curr. Opin. Oncol. (2006) 18(4):341-346.
   PubMed Web of Science ®Google Scholar
• GROSS DJ, MUNTER G, BITAN M et al.: The role of imatinib mesylate (Glivec) for treatment of patients with malignant endocrine tumors positive for c-KIT or PDGF-R. Endocr. Relat. Cancer (2006) 13(2):535-540.
   PubMed Web of Science ®Google Scholar
• HOTTE SJ, WINQUIST EW, LAMONT E et al.: Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-KIT: a Princess Margaret Hospital Phase II consortium study. J. Clin. Oncol. (2005) 23(3):585-590.
   PubMed Web of Science ®Google Scholar
• FAIVRE S, RAYMOND E, CASIRAGHI O, TEMAM S, BERTHAUD P: Imatinib mesylate can induce objective response in progressing, highly expressing KIT adenoid cystic carcinoma of the salivary glands. J. Clin. Oncol. (2005) 23(25):6271-6273; author reply 6273-6274.
   PubMed Web of Science ®Google Scholar
• FROEHNER M, BEUTHIEN-BAUMANN B, DITTERT DD, SCHULER U, WIRTH MP: Lack of efficacy of imatinib in a patient with metastatic Leydig cell tumor. Cancer Chemother. Pharmacol. (2006):1-3.
   Google Scholar
• BASCIANI S, BRAMA M, MARIANI S et al.: Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity. Cancer Res. (2005) 65(5):1897-1903.
   PubMed Web of Science ®Google Scholar
• MIETTINEN M, LASOTA J: KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinicopathologic correlation. Appl. Immunohistochem. Mol. Morphol. (2005) 13(3):205-220.
   PubMedGoogle Scholar
• FIORENTINI G, ROSSI S, LANZANOVA G et al.: Tyrosine kinase inhibitor imatinib mesylate as anticancer agent for advanced ocular melanoma expressing immunoistochemical C-KIT (CD 117): preliminary results of a compassionate use clinical trial. J. Exp. Clin. Cancer Res. (2003) 22(4 Suppl.):17-20.
   PubMed Web of Science ®Google Scholar
• DIRNHOFER S, ZIMPFER A, WENT P: The diagnostic and predictive role of KIT (CD117). Ther. Umsch. (2006) 63(4):273-278.
   PubMedGoogle Scholar
• MOTZER RJ, BERG W, GINSBERG M et al.: Phase II trial of thalidomide for patients with advanced renal cell carcinoma. J. Clin. Oncol. (2002) 20(1):302-306.
   PubMed Web of Science ®Google Scholar
• YOELI-LERNER M, YIU GK, RABINOVITZ I et al.: Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT. Mol. Cell (2005) 20(4):539-550.
   PubMed Web of Science ®Google Scholar
• HUTCHINSON JN, JIN J, CARDIFF RD, WOODGETT JR, MULLER WJ: Activation of Akt-1 (PKB-α) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion. Cancer Res. (2004) 64(9):3171-3178.
   PubMed Web of Science ®Google Scholar
• SAWYERS CL: Will kinase inhibitors have a dark side? N. Engl. J. Med. (2006) 355(3):313-315.
   PubMed Web of Science ®Google Scholar
• BOTTARO DP, LIOTTA LA: Cancer: out of air is not out of action. Nature (2003) 423(6940):593-595.
   PubMed Web of Science ®Google Scholar
• COFFEY JC, WANG JH, BOUCHIER-HAYES D, COTTER TG, REDMOND HP: The targeting of phosphoinositide-3 kinase attenuates pulmonary metastatic tumor growth following laparotomy. Ann. Surg. (2006) 243(2):250-256.
   PubMed Web of Science ®Google Scholar